PROTHENA CORP PUBLIC LTD COPRTAEarnings & Financial Report
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
PRTA Q4 FY2025 Key Financial Metrics
Revenue
$21.0K
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-99.0%
PROTHENA CORP PUBLIC LTD CO Q4 FY2025 Financial Summary
PROTHENA CORP PUBLIC LTD CO reported revenue of $21.0K (down 99.0% YoY) for Q4 FY2025, with a net profit of N/A (up 62.7% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $21.0K |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
PROTHENA CORP PUBLIC LTD CO Annual Revenue by Year
PROTHENA CORP PUBLIC LTD CO annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.7M).
PROTHENA CORP PUBLIC LTD CO Quarterly Revenue & Net Profit History
PROTHENA CORP PUBLIC LTD CO results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $21.0K | -99.0% | N/A | N/A |
| Q3 FY2025 | $2.4M | +149.0% | $-36.5M | -1513.1% |
| Q2 FY2025 | $4.4M | -96.7% | $-125.8M | -2845.4% |
| Q1 FY2025 | $2.8M | +5556.0% | $-60.2M | -2128.5% |
| Q4 FY2024 | $2.1M | +571.8% | N/A | N/A |
| Q3 FY2024 | $970.0K | -98.9% | $-59.0M | -6082.6% |
| Q2 FY2024 | $132.0M | +3184.7% | $66.9M | 50.7% |
| Q1 FY2024 | $50.0K | -97.7% | $-72.2M | -144478.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50000 | $132.0M | $970000 | $2.1M | $2.8M | $4.4M | $2.4M | $21000 |
| YoY Growth | -97.7% | 3184.7% | -98.9% | 571.8% | 5556.0% | -96.7% | 149.0% | -99.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $623.2M | $645.6M | $595.3M | $547.1M | $495.3M | $399.1M | $352.6M | $326.8M |
| Liabilities | $120.8M | $63.6M | $60.9M | $60.2M | $57.7M | $74.7M | $57.6M | $46.3M |
| Equity | $502.4M | $581.9M | $534.4M | $486.9M | $437.7M | $324.3M | $295.0M | $280.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-73.1M | $16.0M | $-45.2M | $-150.1M | $-53.4M | $-46.3M | $-40.6M | $-163.6M |